Patents by Inventor Chester Bittencort SACRAMENTO

Chester Bittencort SACRAMENTO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11883506
    Abstract: Provided herein is a gene therapy for PKP2 (Plakophilin-2), e.g. using an adeno-associated virus (AAV) vector. The promoter of the vector may be a MHCK7 promoter or a cardiac troponin T (HTNNT2) promoter. The capsid may be an AAV9 or AAVrh74 capsid or a functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intravenous, intracoronary, intracarotid or intracardiac administration of the rAAV vector, and other compositions and methods.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: January 30, 2024
    Assignee: Spacecraft Seven, LLC
    Inventors: Christopher Dean Herzog, Chester Bittencort Sacramento, Raj Prabhakar, David Ricks
  • Publication number: 20230272422
    Abstract: Provided herein is a gene therapy for GLUT1 Deficiency Syndrome and related disorders using a recombinant adeno-associated virus (rAAV) virion as a vector to express an GLUT1 protein or functional variant thereof. The rAAV virion may use an endothelial-specific promoter, e.g., a FLT-1 or Tie-1 promoter. The capsid may be an AAV6, AAV8, AAV9, AAVrh.74, or AAVrh.10 capsid or a functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intracerebrally and/or intravenously of the rAAV virion, and other compositions and methods.
    Type: Application
    Filed: August 3, 2021
    Publication date: August 31, 2023
    Inventors: Christopher Dean HERZOG, Chester Bittencort SACRAMENTO, Raj PRABHAKAR, David RICKS
  • Publication number: 20230257431
    Abstract: Provided herein is a gene therapy for CSRP3 (Cysteine and Glycine Rich Protein 3)-related gene deficits associated with cardiomyopathy, e.g. using an adeno-associated virus (AAV) vector. The promoter of the vector may be a MHCK7 promoter or a cardiac troponin T (HTNNT2) promoter. The capsid may be an AAV9 or AAVrh74 capsid or a functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intravenous, intracoronary, intracarotid or intracardiac administration of the rAAV vector, and other compositions and methods.
    Type: Application
    Filed: August 3, 2021
    Publication date: August 17, 2023
    Inventors: Christopher Dean HERZOG, Chester Bittencort SACRAMENTO, Raj PRABHAKAR, David RICKS
  • Publication number: 20230174994
    Abstract: Parkin protein variants having activating mutations and/or fused to a mitochondrial targeting sequence are provided. The engineered Parkin may be a fusion protein including a mitochondrial targeting sequence (MTS); a transmembrane domain; and a Parkin protein or functional variant or fragment thereof, such as a Parkin having an N-terminal deletion. The MTS may be the MTS of PINK1 or a functional variant thereof. Alternatively or in addition, the engineered Parkin may have one or more activating mutations, such as single amino-acid substitutions. The engineered Parkin may be delivered in a vector, such as an adeno-associated virus (AAV) vector, and may be used to treat a disease or disorder, such as Parkinson’s disease or any of various neurodegenerative diseases.
    Type: Application
    Filed: May 20, 2021
    Publication date: June 8, 2023
    Applicant: Spacecraft Seven, LLC
    Inventors: Chester Bittencort SACRAMENTO, Christopher Dean HERZOG, Raj PRABHAKAR
  • Publication number: 20220168446
    Abstract: Provided herein is a gene therapy for PKP2 (Plakophilin-2), e.g. using an adeno-associated virus (AAV) vector. The promoter of the vector may be a MHCK7 promoter or a cardiac troponin T (HTNNT2) promoter. The capsid may be an AAV9 or AAVrh74 capsid or a functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intravenous, intracoronary, intracarotid or intracardiac administration of the rAAV vector, and other compositions and methods.
    Type: Application
    Filed: February 11, 2022
    Publication date: June 2, 2022
    Inventors: Christopher Dean HERZOG, Chester Bittencort SACRAMENTO, Raj PRABHAKAR, David RICKS
  • Publication number: 20220168447
    Abstract: Provided herein is a gene therapy for PKP2 (Plakophilin-2), e.g. using an adeno-associated virus (AAV) vector. The promoter of the vector may be a MHCK7 promoter or a cardiac troponin T (HTNNT2) promoter. The capsid may be an AAV9 or AAVrh74 capsid or a functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intravenous, intracoronary, intracarotid or intracardiac administration of the rAAV vector, and other compositions and methods.
    Type: Application
    Filed: February 11, 2022
    Publication date: June 2, 2022
    Inventors: Christopher Dean HERZOG, Chester Bittencort SACRAMENTO, Raj PRABHAKAR, David RICKS